{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T04:53:09Z","timestamp":1794113589702,"version":"4.8.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"24","license":[{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,26]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Innovation in therapies for patients with von Willebrand disease (VWD) has lagged far behind that for hemophilia, creating inequity in the bleeding disorder community. Although currently existing treatments of antifibrinolytics, desmopressin, and plasma-derived von Willebrand factor replacement are considered effective, multiple studies report poor quality of life in patients with VWD, especially those with heavy menstrual bleeding (HMB). This disconnect underscores the need for novel therapies that are safe and effective and that consider a patient\u2019s specific contraceptive and reproductive needs. Recombinant von Willebrand factor is the most recent new therapy for VWD; the data specific to women are reviewed. We also present emerging data on emicizumab for the treatment of VWD, BT200 (rondoraptivon pegol), generalized hemostatic therapies (VGA039 and HMB-011), as well as treatments based on nanotechnology (platelet-inspired nanoparticles and KB-V13A12). We are optimistic as we move toward pivotal clinical trials for these elegant and innovative treatments.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010716","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T22:00:33Z","timestamp":1700085633000},"page":"7501-7505","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["New and emerging therapies for women, girls, and people with the potential to menstruate with VWD"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8271-6795","authenticated-orcid":false,"given":"Caterina","family":"Casari","sequence":"first","affiliation":[{"name":"1Universit\u00e9 Paris-Saclay, INSERM, H\u00e9mostase Inflammation Thrombose HITH U1176, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2840-7588","authenticated-orcid":false,"given":"Jennifer","family":"Leung","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Queen\u2019s University, Kingston, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4649-9014","authenticated-orcid":false,"given":"Paula D.","family":"James","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Queen\u2019s University, Kingston, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"issue":"5","key":"2023122214570888500_bib1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","article-title":"New therapies for hemophilia","volume":"133","author":"Weyand","year":"2019","journal-title":"Blood"},{"issue":"R1","key":"2023122214570888500_bib2","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1093\/hmg\/ddz157","article-title":"Advances and challenges for hemophilia gene therapy","volume":"28","author":"Batty","year":"2019","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2023122214570888500_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/rth2.12468","article-title":"Sexism in the management of bleeding disorders","volume":"5","author":"Weyand","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2023122214570888500_bib4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/asheducation-2016.1.683","article-title":"New treatment approaches to von Willebrand disease","volume":"2016","author":"Lavin","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"suppl 4","key":"2023122214570888500_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/hae.14518","article-title":"Towards novel treatment options in von Willebrand disease","volume":"28","author":"Lenting","year":"2022","journal-title":"Haemophilia"},{"issue":"10","key":"2023122214570888500_bib6","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor","volume":"4","author":"Sadler","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"issue":"21","key":"2023122214570888500_bib7","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/bloodadvances.2019000368","article-title":"New therapies for von Willebrand disease","volume":"3","author":"Mannucci","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"2023122214570888500_bib8","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2516.2000.00447.x","article-title":"Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey","volume":"6","author":"Kouides","year":"2000","journal-title":"Haemophilia"},{"issue":"7","key":"2023122214570888500_bib9","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/j.1538-7836.2010.03864.x","article-title":"Health-related quality of life among adult patients with moderate and severe von Willebrand disease","volume":"8","author":"de Wee","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2023122214570888500_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/hae.13062","article-title":"Relative contributions of bleeding scores and iron status on health-related quality of life in von Willebrand disease: a cross-sectional study","volume":"23","author":"Xu","year":"2017","journal-title":"Haemophilia"},{"issue":"2","key":"2023122214570888500_bib11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/hae.14725","article-title":"Depression and anxiety in persons with von Willebrand disease","volume":"29","author":"Roberts","year":"2023","journal-title":"Haemophilia"},{"issue":"6","key":"2023122214570888500_bib12","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/jth.15311","article-title":"\u201cThey don\u2019 t really take my bleeds seriously\u201d: barriers to care for women with inherited bleeding disorders","volume":"19","author":"Arya","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"12","key":"2023122214570888500_bib13","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1111\/jth.15102","article-title":"\u201cEverything was blood when it comes to me\u201d: understanding the lived experiences of women with inherited bleeding disorders","volume":"18","author":"Arya","year":"2020","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"2023122214570888500_bib14","doi-asserted-by":"crossref","first-page":"e12652-12","DOI":"10.1002\/rth2.12652","article-title":"The lived experience of women with a bleeding disorder: a systematic review","volume":"6","author":"Sanigorska","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"2023122214570888500_bib15","doi-asserted-by":"crossref","first-page":"100119-5","DOI":"10.1016\/j.rpth.2023.100119","article-title":"Management of heavy menstrual bleeding in women with bleeding disorders in a tertiary care center","volume":"7","author":"Kuthiala","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"17","key":"2023122214570888500_bib16","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","article-title":"Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease","volume":"126","author":"Gill","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2023122214570888500_bib17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood.2021014810","article-title":"Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results","volume":"140","author":"Leebeek","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2023122214570888500_bib18","doi-asserted-by":"crossref","first-page":"e612","DOI":"10.1016\/S2352-3026(23)00119-9","article-title":"Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial","volume":"10","author":"Ragni","year":"2023","journal-title":"Lancet Haematol"},{"issue":"16","key":"2023122214570888500_bib19","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2023122214570888500_bib20","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1111\/hae.14209","article-title":"Effectiveness of emicizumab in preventing life-threatening bleeding complications in type 3 von Willebrand disease with inhibitors: a paediatric report","volume":"27","author":"Cefalo","year":"2021","journal-title":"Haemophilia"},{"issue":"18","key":"2023122214570888500_bib21","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1182\/bloodadvances.2019000656","article-title":"Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies","volume":"3","author":"Weyand","year":"2019","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2023122214570888500_bib22","first-page":"786","article-title":"Treatment with emicizumab leads to clinical improvement in a type 3 von Willebrand disease patient with inhibitor suffering from left ankle arthropathy","volume":"4","author":"Sigaud","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"2023122214570888500_bib23","doi-asserted-by":"crossref","first-page":"102530","DOI":"10.1016\/j.bcmd.2020.102530","article-title":"The potential role of emicizumab prophylaxis in severe von Willebrand disease","volume":"87","author":"Barg","year":"2021","journal-title":"Blood Cells Mol Dis"},{"key":"2023122214570888500_bib24","first-page":"e29060","article-title":"Prophylactic emicizumab in children and adults with type 3 von Willebrand disease","volume":"68","author":"Vo","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2023122214570888500_bib25","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/hae.14491","article-title":"Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): report of two cases and review of literature","volume":"28","author":"Shanmukhaiah","year":"2022","journal-title":"Haemophilia"},{"issue":"5","key":"2023122214570888500_bib26","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/hae.14581","article-title":"Emicizumab enhances thrombus formation in\u00a0vitro under high shear flow conditions in whole blood from patients with type 1 and type 3 von Willebrand disease","volume":"28","author":"Yaoi","year":"2022","journal-title":"Haemophilia"},{"issue":"2","key":"2023122214570888500_bib27","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1111\/hae.14272","article-title":"Emicizumab improves thrombus formation of type 2A von willebrand disease under high shear condition","volume":"27","author":"Yaoi","year":"2021","journal-title":"Haemophilia"},{"issue":"9","key":"2023122214570888500_bib28","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.3324\/haematol.2021.279948","article-title":"The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial","volume":"107","author":"Kovacevic","year":"2022","journal-title":"Haematologica"},{"issue":"23","key":"2023122214570888500_bib29","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1161\/CIRCULATIONAHA.107.724864","article-title":"First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers","volume":"116","author":"Gilbert","year":"2007","journal-title":"Circulation"},{"issue":"18","key":"2023122214570888500_bib30","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1182\/bloodadvances.2022007805","article-title":"The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF\/FVIII in type 2B von Willebrand disease","volume":"6","author":"Ay","year":"2022","journal-title":"Blood Adv"},{"key":"2023122214570888500_bib31","article-title":"Aptamer BT200 prolongs VWF half-life by blocking interaction with macrophage scavenger receptor LRP1","author":"Choin","year":"2023","journal-title":"Int Soc Thromb Haemost"},{"issue":"suppl 1","key":"2023122214570888500_bib32","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2022-170245","article-title":"Pre-clinical characterization of VGA039, an anti-protein S monoclonal antibody being developed as a universal hemostatic agent for various bleeding disorders","volume":"140","author":"Leong","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023122214570888500_bib33","first-page":"18","article-title":"HMB-001 - a novel bispecific antibody with potential for subcutaneous prophylactic treatment of multiple bleeding disorders - initial focus on Glanzmann Thrombasthenia","volume":"28","author":"Gandhi","year":"2022","journal-title":"Haemophilia"},{"issue":"S1","key":"2023122214570888500_bib34","first-page":"103","article-title":"HMB-001 - a novel bispecific antibody accumulating and targeting endogenous FVIIa to activated platelets for subcutaneous prophylaxis in multiple bleeding disorders including Glanzmann thrombasthenia","volume":"6","author":"Ostergaard","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"23","key":"2023122214570888500_bib35","first-page":"2891","article-title":"Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in von Willebrand disease murine models","volume":"141","author":"Roullet","year":"2023","journal-title":"Blood"},{"key":"2023122214570888500_bib36","article-title":"KB-V13A12, a novel nanobody-based therapeutic molecular for the treatment of von Willebrand disease","author":"Peyron","year":"2023","journal-title":"Int Soc Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/24\/7501\/2177853\/blooda_adv-2023-010716-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/24\/7501\/2177853\/blooda_adv-2023-010716-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T14:57:31Z","timestamp":1703257051000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/24\/7501\/498750\/New-and-emerging-therapies-for-women-girls-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":36,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2023,12,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010716","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]}}}